Altered metabolism of daunorubicin and doxorubicin by genetic variants of human aldo-keto and carbonyl reductases
The anthracyclines, doxorubicin (DOX) and daunorubicin (DAUN) are commonly used to treat a variety of cancers. Their use is associated with life-threatening adverse events, especially chronic cardiotoxicity, in some patients. There may be a genetic basis for this variation, arising from altered me...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2010
|
| Online Access: | http://hdl.handle.net/2429/29557 |